Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

ENTX

STRONG SELLREMOVE

Entera Bio Ltd. · Healthcare · Israel · $70M · Avg Vol: $3M/d

4
StockRank
Q
29
V
21
M
25
P/E (TTM)
ROE
-82.3%
D/E
0.0x
Dividend %
AI CONVICTION THESIS

Entera Bio is a speculative biotech company with no commercialized products or stable cash flows, making it unsuitable for a concentrated quality-focused fund.

COMPANY DESCRIPTION

Entera Bio Ltd. is an Israeli clinical-stage biotechnology company specializing in the development of orally administered peptide and protein therapeutics. The company's competitive advantage is its proprietary oral delivery platform, which overcomes the biological barriers of the gastrointestinal tract to deliver large molecules that traditionally require injection. Entera operates as a pioneer in oral peptide delivery, targeting major therapeutic areas such as osteoporosis and hypoparathyroidism with patient-friendly oral alternatives.

FINANCIAL SUMMARY (USD)

Year2022202320242025CAGR
Revenue0.1M00.2M42,000-32.1%
EPS-0.45-0.31-0.25-0.25
Shares28.8M35.5M38.8M46.2M+60.3%
Debt91,0000.4M0.3M0.5M75.3%
Equity11.8M10.4M8.1M13.1M3.7%
Op CF-12.5M-7.3M-6.8M-7.4M
Inv CF-0.1M-17,000-3,000-0.1M
Fin CF13,0006.0M4.5M13.7M
Loading...
PRICE (1Y)+23.2%
1.161.261.351.451.55May 12Jun 3Jun 24
SMA 50SMA 200
Close
$1.54
RSI (14)
75.0
52W High
$3.22
From 52W High
0.5%

SCORE BREAKDOWN

Quality
29
ROIC
-83.6%7.2
ROE
-82.3%9.8
GP/Assets
0.0%9.6
Op. Margin
0.0%40.6
FCF/Assets
-30.3%9.7
Piotroski
25.4
Int. Cover
N/A
D/E Ratio
0.04x75.6
Current Ratio
7.93x82.7
Value
21
P/E (TTM)
N/A
EV/EBITDA
-4.5x25.0
P/FCF
N/A
P/B
7.6x16.3
P/S
0.3
Div Yield
N/A
Momentum
25
52W High %
48%21.6
RS 6M
-21%51.4
SMA 50/200
0.73x7.5
EPS Rev 4W
0.0%49.3
EPS Rev 12W
N/A
EPS Improve
-112%3.8
Q Growth
N/A

FUNDAMENTALS

Market Cap
$70M
P/E (Forward)
-3.2x
Gross Margin
0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ENTX are excluded.

TickerCompanyMkt CapStockRankSignal
ENTXEntera Bio Ltd.(you)$70M4STRONG SELL
PYPDPolyPid Ltd.$92M24SELL
ENLVEnlivex Ltd.$146M18STRONG SELL
SLGLSol-Gel Technologies Ltd.$246M39HOLD
DRTSAlpha Tau Medical Ltd.$890M36HOLD
CGENCompugen Ltd.$196M93STRONG BUY
NNOXNano-X Imaging Ltd.$112M8STRONG SELL
BVC.LBATM Advanced Communications Ltd.$69M56HOLD
1696.HKSisram Medical Ltd$134M64HOLD
BWAYBrainsWay Ltd.$585M83STRONG BUY

Peer medians: ROE 6.5% · P/E 9.9x · Gross margin 36.8%

Entera Bio Ltd. (ENTX) — Stock Score Summary

Entera Bio Ltd. (ENTX) has a MoatMap StockRank of 4/100 based on Quality (29/100), Value (21/100), and Momentum (25/100) factor scores. The current signal is STRONG SELL. Entera Bio is a speculative biotech company with no commercialized products or stable cash flows, making it unsuitable for a concentrated quality-focused fund.

Entera Bio Ltd. is an Israeli clinical-stage biotechnology company specializing in the development of orally administered peptide and protein therapeutics. The company's competitive advantage is its proprietary oral delivery platform, which overcomes the biological barriers of the gastrointestinal tract to deliver large molecules that traditionally require injection. Entera operates as a pioneer in oral peptide delivery, targeting major therapeutic areas such as osteoporosis and hypoparathyroidism with patient-friendly oral alternatives.

Key Financial Metrics

Price$1.54
Market Cap$70M
P/E (Forward)-3.17
Price/Book7.63
Return on Equity-82.3%
Return on Invested Capital-83.6%
Debt/Equity4.19
Gross Margin0.0%
Operating Margin0.0%
Free Cash Flow$-5M

Entera Bio Ltd. operates in the Biotechnology industry, part of the Healthcare sector (Israel).

Frequently Asked Questions

What is Entera Bio Ltd.’s (ENTX) StockRank?
MoatMap’s StockRank for Entera Bio Ltd. (ENTX) is 4/100, with a Strong Sell signal. It is a composite of Quality (29), Value (21), and Momentum (25) factor ranks across MoatMap’s 20,000+ stock universe.
Does Entera Bio Ltd. have an economic moat?
Entera Bio Ltd. (ENTX) has a Quality factor score of 29/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Entera Bio Ltd. a buy, hold, or sell?
MoatMap’s current signal for Entera Bio Ltd. (ENTX) is Strong Sell, based on a StockRank of 4/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Entera Bio Ltd. in?
Entera Bio Ltd. (ENTX) operates in the Healthcare sector, specifically the Biotechnology industry (Israel).